Aflibercept use for CRVO

This review discusses published clinical trial
evidence supporting the use of aflibercept (Eylea®),
an anti-VEGF agent, which is indicated in adults for
the treatment of vision impairment due to macular
oedema secondary to central retinal vein occlusion.
Aflibercept is not currently funded for this indication
under the Pharmaceutical Benefits Schedule.

Please login below to download this issue (PDF)